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Exogenous Progesterone and Progestins as Used in Estrous Synchrony Regimens Do
Not Mimic the Corpus Luteum in Regulation of Luteinizing Hormone
and 17-Estradiol in Circulation of Cows1
N. KOJIMA, T.T. STUMPF,3 AS. CUPP, LA WERTH,4 M.S. ROBERSON,5 M.W. WOLFE,6 LU. KITTOK,
and J.E. KINDER2
Department of Animal Science, University of Nebraska-Lincoln, Lincoln, Nebraska 68583-0908
ABSTRACT
Our working hypothesis was that the low concentrations of progesterone (P4) and synthetic progestins administered in hor-
monal regimens to control estrous cycles of cows would have similar effects on secretion of LH and 17-estradiol (E2). In
addition, we hypothesized that concentrations of exogenous P4 typical of the midluteal phase of the estrous cycle and the corpus
luteum (CL) would have similar effects on LH and E2, and the effects would be different from those of synthetic progestins and
low concentrations of P4. Cows (n = 29) were randomly assigned to one of five treatment groups: I) one Progesterone Releasing
Intravaginal Device (1PRID; n = 6); 2) two PRID5 (2PRID; n = 6); 3) norgestomet, as in Syncro-Mate-8#{174} regimen (SMB; n =
6); 4) melengestrol acetate (MGA; 0.5 mg/day; n = 5); and 5) control (CONT; n = 6). Treatments were administered for 9
days (Day 0 = initiation of treatment). All cows from 1PRID, 2PBJD, SMB, and MGA groups were injected with prostaglandin
F (PGFSJ on Days 2 and 5 of the treatment period to regress CL Cows in the 1PRID and SMB groups were also administered
exogenous estrogen according to the respective estrous synchronization protocol for these products. Daily blood samples were
collected from Day 0 to 35 to determine concentrations of P4. On Day 8, blood samples were collected at 1 5-mm intervals for
24 h to determine pattern of LH secretion. On Day 9, all treatments ceased and cows in the CONT group received injections
of PGF. Blood samples were collected at 1 .h intervals after cessation of treatments to determine time of the preovulatory surge
of UI. During the treatment period, mean concentrations of P4 in 2PRID and CONT groups were greater (p < 0.05) than in
cows from the other groups. Mean concentrations of E2 in cows from the SMB group were greater (p < 0.05) as compared to
cows from the other groups during the treatment period. In addition, concentrations of E2 in cows from the 1PRID group were
greater (p < 0.05) than in cows from the 2PRID and CONT groups. On Day 8 of the treatment period, frequency of UI pulses
in cows treated with SMB was greater (p < 0.05) and mean concentrations of LH in cows from the CONT group were lower
(p < 0.05) as compared to cows from the other groups. Amplitude of UI pulses was not different (p> 0.05) among cows
receiving the various treatments. Initiation of the preovutatory surge of UI was 20 h earlier (p < 0.05) in cows from the SMB
group and tended (p < 0.10) to be earlier in cows from the 1PRID group than cows in the 2PRID and CONT groups. Four of
five cows treated with MGA failed to initiate a preovulatory surge of UI during the sampling period. Concentrations of P4 during
the subsequent estrous cycle were greater ( < 0.05) in cows from 2PRID and CONT groups than in cows from the other
groups. We accept our working hypothesis that secretion of UI is similar in cows treated with the low dose of P4 and synthetic
progestins. However, cows with the higher dose of P4 had a different profile of UI as compared to control cows with their corpus
luteum in situ. Therefore, we reject this part of our working hypothesis.
INTRODUCTiON
Synthetic progestins, melengestro! acetate (MGA) and
norgestomet, have been developed to synchronize time of
ovulation and time of behavioral estrus in the cow by mim-
icking the function of corpus luteum (CL) [1, 2]. However,
use of synthetic progestins has often been associated with
reduced fertility when cows are inseminated during the es-
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trus that results from treatment [2-8]. The reason for re-
duced fertility when MGA (an orally active synthetic pro-
gestin) is used may be due to the increased size of dominant
ovarian follicle(s) that do not ovulate during the treatment
[9-11] and/or to increased concentrations of 173-estradiol
(E2) in circulation [12-14]. A reduction in size and weight
of CL formed after MGA treatment has also been reported
[11]. Use of norgestomet has also been shown to cause a
reduction in fertility [5-8] that may be associated with vari-
ability in timing of onset of the preovulatory surge of W
[15-17] and behavioral estrus [16, 18-20]. The actions of
norgestomet on follicu!ar development may be mediated
by the increased frequency of LH pulses during the period
of norgestomet treatment [21]. An increase in size of ovar-
ian follicles and estrogenic capacity of these follicles has
been reported in postpartum beef cows treated with nor-
gestomet [22, 23]. Norgestomet and MGA may alter ovarian
follicular development via alteration in the secretory pat-
tern of LH. Ovulation of aberrant follicles may lead to de-
fects in function of the CL, known as a luteal phase defi-
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ciency, which has been associated with reduced secretion
of progesterone (P4) and infertility in many species [24-27].
The pattern of pulsatile secretion of LH is modulated by
ovarian steroids, E2 and p4 [28,29]. Administration of low
levels of P4 to cows results in a high frequency of LH pulses
[30,31]. Roberson et a!. [31] reported that concentrations of
E2 are higher and the onset of the preovulatory surge of
LH is earlier after removal of the source of P4 in cows re-
ceiving a low as compared to those receiving a high dose
of P4. These results indicate that lower doses of P4 alter
ovarian activity (increased secretion of E2) during the treat-
ment period and after P4 withdrawal [31].
Few studies have involved administration of synthetic
progestins (MGA and norgestomet) in the regimens used
to control stage of the estrous cycle and compared the se-
cretory pattern of LH under these hormonal regimens to
the way the CL modulates LH secretion. If these hormonal
regimens do not modulate secretion of U-I as does the CL,
then this may help explain the lower fertility that occurs
when these hormonal regimens are used to synchronize
estrus. Therefore, our working hypotheses were as follows:
1) lower doses of P4-resulting in 2-3 ng of circulating P4/
ml of plasma-and MGA or norgestomet administered in
the hormonal regimens used to synchronize estrus would
have similar effects on secretion of UI and E2; and 2) higher
doses of P4-resulting in 7-10 ng of circulating P4/ml of
plasma-and the midluteal phase CL would have similar
effects on secretion of UI and E2, but the effects would be
different from those observed when doses of P4 were lower
and synthetic progestins were administered. Additionally,
function of the CL during the estrous cycle Subsequent to
treatment was characterized.
MATERIALS AND METHODS
E4?erimental Protocol
Twenty-nine mature nonlactating crossbred beef cows
(one-fourth Hereford, one-fourth Angus, one-fourth Pinz-
gaur, one-fourth Red Poll) exhibiting normal estrous cycles
were used in this study (2-5 yr of age; 492 ± 12 kg body
weight, mean ± SEM). Cows were randomly assigned to an
untreated control group (CONT; n = 6) or one of four
treatment groups: 1) one Progesterone Releasing Intrava-
gina! Device with 10 mg E2 benzoate in a gelatin capsule
(PRID; Sanofi Animal Health, Inc., Overland Park, KS), to
provide levels of P4 of 2-3 ng/ml of plasma in circulation
(IPRID; n 6); 2) two PRIDs without E2 benzoate to pro-
vide midluteal phase concentrations (7-10 ng/ml) of ex-
ogenous P4 (2PRID; n = 6); 3) norgestomet, administered
in the Syncro-Mate-B#{174} (Sanoll Animal Health, Inc.) regi-
men, which includes a 6-mg norgestomet ear implant and
an i.m. injection of 5 mg E2 valerate and 3 mg norgestomet
at the time of implant insertion (SMB; n = 6); and 4) MGA
(The Upjohn Co., Kalamazoo, MI) orally at a level of 0.5
mg/cow daily (MGA; n = 5). Stage of the estrous cycle of
cows assigned to these four treatments was not synchro-
nized before the treatment and was completely random.
Stage of the estrous cycle was synchronized in cows from
the CONT group before the initiation of treatments by
administration of two injections of prostaglandin F2 (PGF;
The Upjohn Co., Kalamazoo, MI) given 11 days apart.
Therefore, cows in the CONT group were in the luteal phase
of the estrous cycle during the treatment period. The treat-
ment regimens used with the SMB, MGA, and 1PRID groups
were those recommended when these products are used
commercially for estrous synchronization.
Treatments were administered for 9 days. At the initia-
tion of treatment (Day 0), cows in the 1 PRID and 2PRID
groups received a single PRLD. Additional PRIDs were ad-
ministered to cows in the 2PRID group on Day 1 of the
treatment period to avoid excessive increases in P4 when
two PRIDs are administered on the same day. To maintain
P4 at 7-10 ng/ml of plasma in circulation (2PRID), the PRID
inserted on Days 0 and 1 of the treatment period were re-
placed with new PRIDs on Days 5 and 6, respectively. Cows
in the SMB group received a norgestomet ear implant and
an injection of 5 mg E2 valerate and 3 mg norgestomet at
the initiation of treatment. Cows in the MGA group were
fed their initial MGA on the morning (0800 h) of initiation
of treatments and received the same amount of MGA via
their diet on each day of the treatment period. Cows in the
CONT group were on Day 5 (Day 0 = day of estrus) of
their estrous cycle and received a sham device intravagin-
ally at initiation of treatment. All cows from the 1PRID, 2PRID,
SMB, and MGA groups received injections of PGF2a (25 mg)
on Days 2 and 5 of the treatment period to induce regres-
sion of the CL to eliminate endogenous P4.
On Day 8 of the treatment period, catheters were in-
serted in the jugular vein of all cows and blood samples
were collected at 15-mm intervals for 24 h. All cows were
fed in the middle of the 24-h bleeding period. Therefore,
MGA was fed in the middle of this period. These blood
samples were used to compare pulse frequency of UI of
cows in the different treatment groups. On Day 9 of the
treatment period, PRIDs and norgestomet implants were
removed from cows in the 1PRID, 2PRID, and SMB groups;
the last feeding of MGA wss given to cows in the MGA group,
and cows in the CONT group received an injection of PGF215
(25 mg). Blood samples were collected at hourly intervals
for 75 h (1PRID, 2PRID, and SMB groups) or 100 h (MGA
and CONT groups) after removal of PRID5, norgestomet im-
plants, last feeding of MGA, and the injection of  These
blood samples were used to determine timing to the pre-
ovulatory surges of UI, FSH, and pattern of E2 during the
follicular phase that followed progestin or P4 withdrawal or
the injection of PGF2a.
Blood samples collected at 1 5-mm and hourly intervals
were allowed to clot at room temperature and then stored
at 4#{176}Cfor 24 h. Samples were then centrifuged at 1520 X
g for 15 mm, and serum was decanted and stored at -20#{176}C
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TABLE 1. Mean concentrations of P4. area under the curve for the profile of P4 in circulation, and duration of the
luteal phase following treatment.
Subsequent estrous
Treatment period cycleb
Luteal
Mean P4 Areac Mean P4 Areac phased
Treatment#{176} n (ng/ml) (units) (ng/ml) (units) Cd)
1PRID 6 3.9#{176} 623.3#{176} 4.3#{176} 691.1#{176} 16.3
SMB 6 1.4’ 216.7’ 2.7#{176} 493.0#{176} 15.3
MGA 5 2.4’ 344.9’ 3.4#{176} 513.0#{176} 16.4
2PRID 6 10.1 1542.1 7.3’ 1376.5’ 18.7
CONT 6 9.0 1301.4#{176} 7.6’ 1106.4’ 18.3
Pooled SEM5 2.7 216.2 2.0 399.3 2.9
#{176}SeeMaterials and Methods for definition of abbreviations and explanations of Progesterone Releasing Device with
10 mg E2 treatment regimens.
bEstrous cycle following removal of all treatments.
cArea under the curve for concentrations of P4 expressed in arbitrary units.
4lnterval between first rise in P4 above 1 ng/ml and decline in P4 below 1 ng/ml of plasma.
#{176}‘Numbers with differing superscripts within column differ (p < 0.05).
5Pooled standard error of mean (SEM).
until assayed for UI, FSH, and E2. All serum samples col-
lected at 1 5-mm and hourly intervals were pooled for 4-h
periods within each cow to determine concentrations of
FSH and E2.
Blood samples were collected daily from all cows to
evaluate plasma concentrations of P4 (sample tubes treated
with 30% solution of EDTA, 50 !/10 ml of blood sample;
Fisher Scientific, Co., Fair Lawn, NJ) throughout the treat-
ment period, and then were collected every other day for
26 days post-treatment for the estrous cycle subsequent to
treatment. To avoid possible degradation of P4 in blood,
these samples were placed on ice immediately and plasma
was separated from blood cells by centrifugation at 1520 X
g for 15 mm within 1 h of collection. Plasma was then har-
vested and stored at - 20#{176}Cuntil assayed for P4.
Radioimmunoassays
Concentrations of UI in all samples collected serially were
analyzed by radioimmunoassay [32], validated in our lab-
oratory [33], using rabbit antiserum against ovine UI (TEA-
RAOLH #35) provided by Dr. Jj. Reeves (Washington State
Univ., Pullman, WA), highly purified ovine UI (LER-1374A)
as radiolabeled tracer, and NIH-UI-B7 as standard. Intra-
and mnterassay coefficients of variation for UI assays were
2.9 and 11.6%, respectively. Concentrations of FSH in all
pooled serum samples were analyzed by radioimmunoas-
say [34], validated in our laboratory [33], using rabbit anti-
serum against ovine FSH (JAD-RAOFSH #17-6,7,9) pro-
vided by Dr. JA Dias (New York State Dept. of Health, Albany,
NY), and highly purified ovine FSH (LER-1976-A2) as radio-
labeled tracer and standard. Intra- and interassay coeffi-
cients of variation for FSH assays were 2.2 and 4.5%, re-
spectively. Concentrations of P4 in plasma samples collected
throughout the experiment were analyzed by radioimmu-
noassay, as validated in our laboratory [31]. This procedure
used a monoclona! antibody (02-9B4-94) to P4-11-BSA
(BiosPacific, Emeryvi!le, CA), P4- 11 a-hemisuccinate-TME
provided by Dr. A. Belanger (Le Centre Hospitalier de
I’Universite Lava!, PQ, Canada) as radiolabeled tracer, and
P4 (Sigma Chemical Co., St. Louis, MO) as standard. Intra-
and interassay coefficients of variation for P4 assays were
6.3 and 12.3%, respectively.
Concentrations of E2 in all pooled serum samples were
analyzed by radioimmunoassay which utilized an antiserum
(Lilly lot #022367) provided by Dr. N.R Mason (Lilly Re-
search Laboratories, Indianapolis, IN), 1251-E2 (IMS. 135;
E2-6[O-carboxymethyl]oximino-2[1251]iodohistamine, Amer-
sham Corporation, Arlington Heights, IL) as radiolabeled
tracer, and E2 (Sigma Chemical Co., St. Louis, MO) as stan-
dard. Assay validation and procedures using this antiserum
have been reported [35-37]. Antiserum to E2 was used at a
dilution of 1:1 000 000. Serum samples were extracted twice
with 2 ml of diethyl ether. Recovery of [3H]E2 averaged 87.4
± 2.3% in eight assays, and sample values were corrected
for extraction efficiency. Recovery of added mass (0.1, 0.2,
and 6.4 pg E2) from 200 ! of serum from each of three
independent serum samples averaged 99.4 ± 2.9%. Assay
determinations of 100 and 200 tl of sample from each of
ten independent serum samples were highly correlated (100
and 200 1.d, r = 0.969). The amount of E2 in each of the
unknown samples was determined with a Four Parameter
Curve Fitting Program [38]. Intra- and interassay coefficients
of variation for E2 assays were 2.6 and 19.3%, respectively.
Mean concentrations of UI (ng/ml) in serum samples,
frequency of pulses of UI (pulses/24 h), and amplitude of
pulses of UI (ng/ml) were determined through the use of
algorithms (Pulsar software modified for the IBM-PC byJ.F.
Gitzen and V.D. Ramirez, Univ. of Illinois, Urbana, IL). In-
terval to the initiation of the preovulatory surge of UI was
defined as the number of hours between cessation of treat-
ments and the initiation of a continuous high-amplitude rise
in concentrations of UI. Area under the P4 release curve
IS
1$
14
Is
12
E 11
0
TABLE 2. Mean concentrations of E2 during the treatment period, on
Day 8 of treatment, and on Day 9, at the time of cessation of treatments.
0 1 2
#{176}SeeMaterials and Methods for definition of abbreviations and explanation
of treatment regimens.
bDuring 9-day treatment period.
cAt serial blood collection on Day 8 of treatment.
2 4 $ S 7 S S 4At time of treatment cessation on Day 9.
Day of Tr.atm.nt #{176}‘#{176}Numberswith differing superscripts within column differ (p < 0.05).
hPooied standard error of mean (SEM).
FIG. 1. Mean concentrations of progesterone in plasma samples dur-
ing the treatment period (1PRID, n = 6; SMB, n = 6; MGA, n = 5; 2PRID;
n = 6; CONT, n = 6). Pooled standard error of mean was 2.1 ng/mi.
I
0
70
SO
40
SO
20
10
0
#{149}.-
-- _________
0  S
Day of Treatment
FIG. 2. Mean concentrations of 17-estradiol in plasma samples dur-
ing the treatment period (1PRID, n = 6; SMB, n = 6; MGA, n = 5; 2PRID;
n = 6; CONT, n = 6). Pooled standard error of mean was 14.92 pg/mI.
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during the treatment period and the estrous cycle following
cessation of treatments was determined by measurement
with a planimeter. The length of the luteal phase during
the estrous cycle subsequent to treatment was determined
by calculating the number of days between the first rise in
P4 above 1 ng/ml early and decline below 1 ng/ml of plasma
late in the estrous cycle.
Statistical Analysis
Data were analyzed as a completely random design [39].
Data regarding the pulsatile secretion of UI on Day 8 of
treatment, interval to the preovulatory surge of UI, and mean
concentrations of E2 and P4 during the treatment period
and the subsequent estrous cycle after cessation of treat-
ment were examined by analysis of variance (ANOVA) us-
ing the general linear models procedure of SAS [40]. Treat-
ment means were compared by orthogonal contrasts [40].
Area under curve for P4 during the treatment period and
the subsequent estrous cycle were analyzed by ANOVA us-
ing the genera! linear models procedure of SAS [40].
RESULTS
Hormone Concentrations during Treatment Period
During the 9-day treatment period, mean concentrations
of P4 (Table 1) in cows treated with two PRIDs and cows
from the CONT group were higher (p < 0.05) than in cows
from the 1PRID, SMB, and MGA groups. Cows treated with
two PRIDs had similar mean concentrations of P4 as com-
pared to cows from the CONT group. Area under the curve
for P4 (Table 1) during the treatment period was greater
(p < 0.05) in cows treated with two PRIDs and cows from
the CONT group than cows from the other groups. Mean
concentration of E2 (Table 2) in cows from the SMB group
Mean c oncentrations of E2
During
treatmentb Day 8#{176} Day 94
Treatment#{176} n (pg/mi) (pg/mi) (pg/mi)
1PRID 6 8.4’ 7.6’ 7719
SMB 6 353e 16.5#{176} 17.8#{176}
MGA 5 6.9’s 10.4’ 12.2#{176}’
2PR1D 6 399 2.5 439
CONT 6 3.0 2.1 3.2
Pooled SEMh 5.1 4.6 4.5
(35.3 ± 11.1 pg/m!) was higher (p < 0.05) compared to
that of cows from the other groups. Mean concentration of
E2 in cows from the 1PRID group (8.4 ± 1.4 pg/mI) was
higher (p <0.05) than in cows from the 2PRID and CONT
groups (3.9 ± 0.6 and 3.0 ± 0.3 pg/mI, respectively) dur-
ing the treatment period. These higher concentrations of
E2 in cows from SMB and 1 PRID groups were due to their
treatment with E2 valerate or E2 benzoate, respectively. Fig-
ures 1 and 2 depict mean concentrations of P4 and E2, re-
spectively, for all treatment groups during the treatment pe-
riod.
Hormone Concentrations during Serial Blood Collection
Period
On Day 8 of treatment, mean concentrations of UI (Ta-
ble 3) were lowest (p < 0.05) in cows from the CONT
group (0.48 ± 0.06 ng/m!). Frequency of UI pulses (Table
--.-.-.- 1PRID
8MB
MQA
-------#{149}---- 2PRID
CONT
0 4 9 12 15  24
Hour
FIG. 3. Secretory profile of LH from individual representative animals
from each treatment group during serial blood collection on Day 8 of treat-
ment.
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TABLE 3. Mean concentrations of P, mean concentrations of LH, and amplitude and frequency of pulses of LH
on Day 8 of treatment.
Treatment#{176} n
Mean P4
(ng/mI)
Mean LHb
(ng/ml)
LH frequencyb
(pulses/24h)
LH amplitud&’
(ng/ml)
1PRID 6 1.9’ 0.8#{176} 118d 11
SMB 6 03’ 1.1C 18.8’ 1.1
MGA 5 1.7c 1.1’ 134d 1.5
2PRID 6 8.5 0.8’ 95d 1.3
CONT 6 10.2#{176} 0.5 2.5#{176} 1.7
Pooled SEM’ 1.4 0.1 3.0 0.8
#{176}SeeMaterials and Methods for definition of abbreviations and explanation of treatment regimens.
bDetermined with Pulsar software.
cdeNumbers with differing superscripts within column differ (p < 0.05).
‘Pooled standard error of mean (SEM).
3) was highest (p < 0.05) in cows from the SMB group
(18.83 ± 1.11 pulses/24 h) and was lowest (p < 0.05) in
cows from the CONT group (2.50 ± 0.43 pulses/24 h) as
compared to cows in other groups. Frequency of UI pulses
did not differ (p > 0.05) between cows from the 1PRID,
MGA, and 2PRID groups (11.83 ± 1.35, 13.40 ± 1.91, and
9.50 ± 1.23 pu!ses/24 h, respectively). Amplitude of UI
pulses (Table 3) was not different (p > 0.05) among the
five groups of cows. Figure 3 depicts data from individual
S.
C
0
C,,)
representative cows from each treatment group for pulsa-
tile secretory profile of UI in circulation on Day 8 of treat-
ment. Mean concentrations of P4 (Table 3) were higher (p
<0.05) in cows treated with two PRIDs (8.5 ± 0.9 ng/ml)
and cows from the CONT group (10.2 ± 0.6 ng/ml) as
compared to cows in the other groups. During serial blood
collection, mean concentrations of E2 (Table 2) in cows from
the 1PRID and SMB groups (7.6 ± 2.0 and 16.5 ± 3.0 pg/
ml, respectively) were higher (p < 0.05) than in cows from
the 2PRID and CONT groups (2.5 ± 0.3 and 2.1 ± 0.2 pg/
ml, respectively).
Hormone Concentrations after Cessation of Treatment
After cessation of treatments on Day 9, initiation of the
preovulatory surge of UI (Table 4) was 20 h earlier (p <
0.05) in cows from the SMB group (45 h) and tended (p
<0.10) to be earlier in cows from the 1PRID group (51 h)
than in cows from the 2PRID (65 h) and CONT (65 h) groups.
The preovulatory surge of FSH was observed concomitantly
with the UI surge (data not shown). Four of five cows treated
with MGA failed to initiate a preovulatory surge of UI within
the 100-h blood sampling period after treatment removal.
Mean concentrations of E2 (Table 2) were higher (p <
0.05) in cows from the SMB group (17.8 ± 2.5 pg/rn!) as
compared to cows from the 1PRID, MGA, 2PRID, and CONT
groups (7.7 ± 1.5, 12.2 ± 3.3, 4.3 ± 0.5, and 3.2 ± 0.4 pg/
ml, respectively) at the time of cessation of treatments. A
continuous increase in concentrations of E2 was observed
in cows that initiated the preovu!atory surge of LH. Figure
4 depicts mean concentrations of E2 from cows in the 1PRID,
SMB, 2PRID, and CONT groups during the follicular phase
of the estrous cycle subsequent to cessation of treatments.
Mean concentrations of P4 and area under the curve for
P4 (Table 1) during the estrous cycle subsequent to treat-
ments were higher (p < 0.05) in cows treated with two
PRIDs and cows from the CONT group than cows from the
1PRID, SMB, and MGA groups. Duration of the luteal phase
(Table 1) was not different (p > 0.10) between cows from
the five treatment groups.
o 4 S 12 II 20 24 25 $2 $1 40 44 4$
Hour After Trstment CessatIon
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TABLE 4. Interval to the preovulatory surge of LH following cessation of
treatment.
Treatment’
Number of
anlmalsb
Interval to LII
surge (h)’
1PRID 4 51’
8MB 4 454
MGA4 1 (68)
2PRID 4 65’
CONT 5 65’
Pooled SEM9 8.16
‘See Materials and Methods for definition of abbreviations and explanation
of treatment regimens.
bNumber of animals initiating the preovuIatory surge of LH during the 75
or 100 h after cessation of treatment.
‘Interval of time from treatment cessation to initiation of the preovulatory
surge of LII.
4Four of five cows treated with MGA did not Initiate a preovulatory surge
of LH during the 100-h blood collection.
“Numbers with differing superscripts within column differ (p < 0.05).
9Pooled standard error of mean (SEMI.
DISCUSSION
Synchronization of estrus with synthetic progestins (nor-
gescomet and MGA) In groups of cows has often been as-
sociated with reduced fertility at the synchronized estrus.
Results from the present study indicate that synthetic pro-
gestins administered In the regimen used to synchronize
estrus do not mimic the function of CL in regulation of
pulsatile secretion of LII and ovarian activity. During the
serial blood collection on Day 8 of treatment, frequency of
[J.j pulses was highest in cows from the SMB group, whereas
frequency did not differ among cows from the 1 PR!D, MGA,
and 2PRII) groups. This higher frequency of Lii pulses ob-
served in cows from the 8MB group is more characteristic
of the pattern normally observed during the follicular phase
of the estrous cycle [41, 421 and is in agreement with pre-
vious results 1211. An increase in Lii pulse frequency with
lower doses of P4 ha,s aLso been reported previously [30, 31].
In contrast, frequency of Lii pulses was lowest for cows In
the CONT group in the present study. This was in agree-
ment with results from previous research 131,41,431.
Cows from the 2PRID group failed to exhibit an LI I pulse
frequency similar to cows from the CONT group. Similar
results have been observed previously in our laboratory [31J.
Mean plasma concentr,itions of P4 during the treatment pe-
riod were similar in cows from the 2PRID (10.1 ng/ml) and
CONT (9.0 ng/ml) groups. At the time of serial blood col-
lection (Day 8), cows from the 2PRID group had lower (P
< 0.05) concentrations of P4 (8.5 ng/ml) than COW5 from
the CONT group (10.2 ng/rnl) that were in the midluteal
phase of their estrous cycles. There are several possible ex-
planations for the difference in LII pulse frequency be-
tween cows receiving exogenous P4 that results In circu-
lating concentrations of P.1 typical of the midluteal phase
(2PRID) and cows in the midluteal phase of the estrous
cycle (CONT). In the present study, PRIDs were replaced
with new PR1Ds at 5-day intervals In COWS from the 2PRII)
group. This regimen was based on data obtained from our
previous study [31], which showed that concentrations of
P4 begin to decline after 5 days from insertion of PRIDs.
Consequently, new PRIDs had been in place for 2 and 3
days when serial blood samples were collected on Day 8
of treatment in the present study. However, even after 2
and 3 days from the time of replacement of PRID5, mean
concentrations of P4 had declined (on Day 8 of treatment)
in cows from the 2PRII) group. In contrast, cows from the
CONT group had continuously increased concentrations of
P4 as the luteal phase progressed (Fig. 1). These differences
in concentrations of P4, either increasing or declining, may
contribute to the pattern of pulsatile secretion of LI-i ob-
served in our study. The 1.7-ng difference in concentration
of P4 on the day of serial blood collection may also con-
tribute to differences in pulsatile secretion of LII between
these two groups of cows. Another possibility is that the CL
produces a factor(s) other than P4 that may influence LI-I
pulse frequency. Yet another possibility is that the profile
of P4 in circulation has less variation when the source of P4
is exogenous as compared to that produced by the CL and
that this variation is related to modulation of LII secretion.
However, comparison of profiles of P4 in circulation in cows
from the 2PRID and CONT groups lead us to believe that
there is equal variance in P4 concentrations in circulation
among animals from these two groups.
Mean concentrations of E2 were not different among cows
from the 2PRID and CONT groups either during the treat-
ment period or on the day of serial blood collection. These
results indicate that the differing patterns of Lii in circu-
lation were not caused by major shifts in P4:E2 ratio, which
has been proposed as a determining factor in the pattern
of LH in circulation 128, 291, While it is clear that P4 is a
I
I
I
FiG. 4. Mean concentrations of 17-estradioI in pooled serum samples
(every 4 h) after treatment cessation (1PRID, ri - 4; 8MB, n 4; 2PRID, n
#{149}; CONT, n - 5; n #{149}number of animals initiating the preovuletory surge
of LH during the 75 or 100 h after cessation of treatment). Only one animal
treated with MGA had a preovulatory surge of LH during the period of blood
collection after cessation of treatment. Thus, data from this group are not
depicted. Pooled standard error of mean was 7.9 pg/mi.
PROGESTINS AND PROGESTERONE ON LH AND E2 1015
modulator for the pulsatile secretion of UI, other factors
produced by the CL may modulate the pattern of LII in
circulation.
On Day 8 of the treatment period, mean concentrations
of E2 were greater in cows from the SMB group than in
other groups and were similar in cows from the 1PRID and
MGA groups. In contrast, mean concentrations of E2 were
significantly lower in cows from the 2PRID and CONT groups
as compared to other treatment groups. The concentrations
of E2 and frequency of UI pulses were positively correlated
(p < 0.0001); SMB (16.5:18.8)> MGA (10.4:13.4)> 1PRID
(7.6:11.8)> 2PRID (2.5:9.5) > CONT (2.1:2.5, pg of E2/
ml plasma:W pulses/24 h, respectively). The differences in
concentrations of E2 in circulation in cows treated with syn-
thetic progestins may be caused by a greater LII pulse fre-
quency which in turn may alter ovarian follicular devel-
opment and further increase concentrations of E2. It has
been reported that cows treated with norgestomet have an
increased frequency of UI pulses [21] and elevated circu-
lating concentrations of E2 [22], which are associated with
increased size, estrogenic capacity [22], and number of UI
receptors [23] of the largest ovarian follicle. Treatment with
MGA has been shown to increase size of ovarian follicles
[9, 10] and concentrations of E2 in circulation of cows [13, 141.
Interestingly, effects of synthetic progestins on pattern of
LII pulse frequency are abolished by the presence of the
CL [44].
In general, increasing concentrations of E2 after a de-
cline in P4 will induce a preovulatory surge of UI in cows
[45,46]. In the present study, concentrations of E2 were
greater in cows from the 1PRID or SMB groups than cows
from the 2PRID or CONT groups throughout the follicular
phase following cessation of treatments on Day 9. Subse-
quently, the initiation of the preovulatory surge of UI oc-
curred earlier in cows from the 1PRID or SMB groups. These
results indicated that follicular maturation might have been
in a more advanced stage in cows from the 1PRID and SMB
groups as compared to cows from the 2PRID and CONT
groups. Results from cows in the 1PRID group are in agree-
ment with those of Roberson et al. [311 who reported that
cows treated with a half PRID without the gelatin capsule
containing E2 had an increased concentration of E2 in cir-
culation during the treatment period. In that study, cows
treated with a half PRID also had increased E2 during the
early portion of the follicular phase following cessation of
treatment and an earlier preovulatory surge of LII as com-
pared to cows from a 2PRID or control group [31]. Several
studies have been reported in which cows treated with nor-
gestomet initiate preovulatory surges of UI 30-48 h after
implant removal [15-17], which is in agreement with re-
sults of the present study.
Four of five cows treated with MGA failed to initiate a
preovulatory surge of UI within the 100-h blood sampling
period following cessation of treatment. The failure of ini-
tiation of the preovulatory surge of LII in cows treated with
MGA might be associated with circulating concentration of
P4. Three of four MGA-treated cows that did not initiate the
UI surge had more than 1 ng/ml of P4 in circulation
throughout the treatment period. Despite two injections of
PGF2a, concentrations of P4 were not maintained at basal
concentrations in these cows. We have no explanation for
this phenomenon at this point; however, MGA may cause
luteinization of the cells [101 that make up the ovarian fol-
licles to the point that production of some P4 occurs. All
cows (38%) that did not initiate a preovulatory surge of U-i
during the blood sampling period (75 or 100 h) had in-
creased concentrations of P4 within 10 days after cessation
of treatment. These cows presumably had a delayed pre-
ovulatory surge of UI beyond the hourly blood collection
period (75 or 100 h, depending on treatment).
Recently, Sirois and Fortune [47] demonstrated, by using
real-time ultrasonography, that subtle changes in the hor-
monal milieu (levels of P4) can dramatically alter the pat-
tern of ovarian follicular dynamics. Administration of the
low doses of P4 at the time of natural luteolysis causes ces-
sation of normal ovarian follicular recruitment and atresia.
This results in a prolonged development of the ovulatory
(or largest) follicle, which is dominant at the time of nat-
ural luteolysis. It was also reported that greater concentra-
tions of E2 are observed in cows treated with low doses of
P4 as compared to nontreated cows during the treatment
period. According to these observations, ovarian follicular
maturation in cows treated with the lower doses of P4 in
the present study might have been more advanced at the
time of cessation of treatments. Thus, the shortened interval
to the preovulatory surge of UI could have resulted. It has
been suggested that aberrant ovarian follicular develop-
ment is closely associated with function of subsequent CL
[26]. Murdoch et al. [27] demonstrated that premature in-
duction of ovulation by intrafollicular injection of gonad-
otropins results in luteal phase deficiency in the ewe.
These observations allow us to hypothesize that a pro-
longed development of the dominant ovarian follicle re-
sults when low concentrations of P4 or synthetic progestins
persist in circulation. The prolonged dominance of this
ovarian follicle may lead to development and ovulation of
an abnormal oocyte that is less fertile. Defects in function
of CL after ovulation of this abnormal follicle may also oc-
cur. Another reason for the reduced fertility in cows treated
with synthetic progestins is that alterations in their hor-
monal milieu (hyperestrogenic environment) may occur that
lead to abnormal uterine conditions [48] and contractions
[49, 50]. Doses of P4 that mimic circulating concentrations
typical of the midluteal phase of the estrous cycle may have
the potential to synchronize estrus without reducing fertil-
ity.
In summary, the low levels of P4 and synthetic progestins
(norgestomet and MGA) administered in the regimen used
to synchronize estrus alter the pattern of pulsatile secretion
of UI and apparent ovarian activity, which is indicated by
1016 KOJIMA ET AL.
the increased secretion of E2 during the later part of the
treatment period and subsequent follicular phase. These
treatments also induced apparent luteal phase deficiency
during the estrous cycle subsequent to treatment. These
observations suggest that abnormal development of ovarian
follicles by the alteration in secretion pattern of UI could
lead to production of an abnormal oocyte that would be
less fertile and ovulation of an abnormal follicle that may
lead to altered function of the subsequent CL. The 2PRID
treatment that resulted in midluteal phase concentrations
of P4 did not mimic the functions of midluteal phase CL in
modulating the pattern of UI in circulation. Further studies
are needed to investigate in more detail the follicular de-
velopment and CL function associated with treatment with
synthetic progestins. Based on data from our present re-
search, synchronization of estrus with levels of P4 that mimic
midluteal concentrations may lead to improved conception
rates at synchronized estrus, with conception rate compa-
rable to those observed at spontaneous estrus.
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